TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16)

被引：2

作者：

Hess, D. ^{[1
]}

Colombo, I. ^{[2
]}

Haefliger, S. ^{[3
]}

Bastian, S. ^{[4
]}

Rabaglio, M. ^{[3
]}

Metaxas, Y. ^{[5
]}

Eckhardt, K. ^{[6
]}

Kopp, C. ^{[6
]}

Hayoz, S. ^{[6
]}

Mueller-Schoell, A. ^{[7
]}

Kloft, C. ^{[7
]}

Sessa, C. ^{[2
]}

Stathis, A. ^{[2
]}

Joerger, M. ^{[8
]}

机构：

[1] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland

[2] Oncol Inst Southern Switzerland, Dept Med Oncol, Bellinzona, Switzerland

[3] Univ Hosp, Dept Med Oncol, Bern, Switzerland

[4] Kantonsspital Graubunden, Dept Med Oncol, Chur, Switzerland

[5] Kantonsspital Graubunden, Oncol Hematol, Chur, Switzerland

[6] Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland

[7] Free Univ Berlin, Inst Pharm, Dept Clin Pharm & Biochem, Berlin, Germany

[8] Kantonsspital St Gallen, Med Oncol & Hematol Dept, St Gallen, Switzerland

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.689

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

575P

引用

页码：S490 / S490

页数：1